Progressive osseous heteroplasia controlled by intravenous administration of pamidronate [6]

American Journal of Medical Genetics

Volumn 140 A, Issue 8, 2006, Pages 910-913

  Hou, Jia Woei ^a  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; GENOMIC DNA; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PROCOLLAGEN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

BONE DENSITY; BONE MALFORMATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DERMIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE SEQUENCE; HETEROTOPIC OSSIFICATION; HUMAN; LETTER; NUCLEIC ACID BASE SUBSTITUTION; OSTEOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSIVE OSSEOUS HETEROPLASIA; SKIN BIOPSY; SUBCUTANEOUS FAT;

ADULT; BONE DENSITY CONSERVATION AGENTS; CHILD, PRESCHOOL; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; MALE; OSSIFICATION, HETEROTOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN ABNORMALITIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645571546     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31200     Document Type: Letter

References (11)

1. Ahrens W, Hiort O, Staedt P, Kirschner T, Marschke C, Kruse K. 2001. Analysis of the GNAS1 gene in Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 86:4630-4634.
2. Aynaci O, Mujgan Aynaci F, Cobanoglu U, Alpay K. 2002. Progressive osseous heteroplasia. A case report and review of the literature. J Pediatr Orthop 811:339-342.
3. Blaszczyk M, Majewski S, Brzezinska-Wcislo L, Jablonska S. 2003. Fibrodysplasia ossificans progressiva. Eur J Dermatol 13:234-237.
4. Devogelaer JP. 2000. Long-lasting effect of pamidronate on bone metabolism in osteoporosis after stopping therapy. J Musculoskele Neuronal Interact 1:149-151.
5. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML. 2003. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 11:573-578.
6. Kaplan FS, Craver R, MacEwen GD, Gannon FH, Finkel G, Hahn G, Tabas J, Gardner RJ, Zasloff MA. 1994. Progressive osseous heteroplasia: A distinct developmental disorder of heterotopic ossification: two new case reports and follow-up of three previously reported cases. J Bone Joint Surg 74A:425-436.
7. Kaplan FS, Glaser DL, Hebela N, Shore EM. 2004. Heterotopic ossification. J Am Acad Orthop Surg 12:116-125.
8. Schuetz P, Mueller B, Christ-Crain M, Dick W, Haas H. 2005. Amino-bisphosphonates in heterotopic ossification: First experience in five consecutive cases. Spinal Cord 43:604-610.
9. Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, Gardner RJ, Zasloff MA, Whyte MP, Levine MA, Kaplan FS. 2002. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 346:99-106.
10. Srivastava T, Alon US. 2003. The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162:735-751.
11. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. 2003. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111: 1030-1036.